Production & Sales

Dr. Reddy’s Laboratories to acquire select business divisions of Wockhardt in India

Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.1850 Crores.

Apollo to buy speciality pharmaceutical company Covis Pharma

Apollo Global Management has agreed to acquire the Netherlands-based speciality pharmaceutical company Covis Pharma from Cerberus Capital Management for an undisclosed sum.

Allergan to sell brazikumab and Zenpep to close $63bn deal with AbbVie

Allergan has agreed to sell brazikumab (formerly MEDI2070) and Zenpep (pancrelipase) to AstraZeneca and Nestle, respectively, in separate deals, for an undisclosed price.

Atnahs Pharma to buy AstraZeneca’s hypertension medicines in $390m deal

Atnahs Pharma has agreed to acquire hypertension medicines from AstraZeneca in a deal valued at around $390m.

Calidi Biotherapeutics secures series A investments to advance manufacturing

Calidi Biotherapeutics, a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two South Korean firms to advance manufacturing in preparation for Calidi's pre-IND and IND filings.

Eli Lilly to build $470m pharmaceutical manufacturing facility in North Carolina

Eli Lilly is set to invest more than $470m to build a new pharmaceutical manufacturing facility in North Carolina, US.

Armas Pharmaceuticals adds four generic injectables as first launches of 2020

The products are now a part of Armas' consistently growing product line, bringing their portfolio count to eleven

Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US

Bayer has entered into a licence agreement with Daré Bioscience to commercialise investigational contraceptive product called Ovaprene in the US.

Charles River Laboratories wraps up $380m acquisition of HemaCare

Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.